Cui-Jie Shao1, Jun Fu, Hong-Liu Shi, Yong-Gao Mu, Zhong-Ping Chen. 1. State Key Laboratory for Cancer Research in Southern China, Department of Neurosurgery/Neuro-oncology, Cancer Center, Sun Yat-Sen University Guangzhou, Guangdong, P.R. China.
Abstract
OBJECTIVE: This study was designed to investigate the relationship between activities of DNA-dependent protein kinase (DNA-PK), its subunits Ku86/Ku70, and sensitivities to cisplatin in human glioma samples. METHODS: Thirty-six glioma samples from patients without prior treatment before neurosurgery were included in this study. The sensitivities to cisplatin as indicated by IC(50) (the inhibitory concentration leading to 50% cell death) were assessed by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenytetrazolium (MTT) assay; activities of DNA-PK and Ku70/Ku86 were analyzed by SigmaTECT DNA-Dependent Protein Kinase Assay System and Ku70/Ku86 DNA Repair Kit, respectively. RESULTS: Sensitivities to cisplatin correlated with the activities of DNA-PK/Ku86, but not with the Ku70 or other clinical parameters such as age, sex of the patients, pathological gradings of the tumors, or tumor size. The levels of DNA-PK activities also associated with pathological grading and Ku86, but not with other clinical parameters. The tumors of the patients who failed to respond to cisplatin-based chemotherapy tended to display higher activity levels of DNA-PK and Ku86. Furthermore, platinum-based chemotherapy did not result in significant changes of DNA-PK/Ku activities in four matched samples before and after chemotherapy. CONCLUSION: Pretreatment determination of DNA-PK/Ku86 activities might be helpful in identifying patients who will actually benefit from platinum-based treatment.
OBJECTIVE: This study was designed to investigate the relationship between activities of DNA-dependent protein kinase (DNA-PK), its subunits Ku86/Ku70, and sensitivities to cisplatin in humanglioma samples. METHODS: Thirty-six glioma samples from patients without prior treatment before neurosurgery were included in this study. The sensitivities to cisplatin as indicated by IC(50) (the inhibitory concentration leading to 50% cell death) were assessed by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenytetrazolium (MTT) assay; activities of DNA-PK and Ku70/Ku86 were analyzed by SigmaTECT DNA-Dependent Protein Kinase Assay System and Ku70/Ku86 DNA Repair Kit, respectively. RESULTS: Sensitivities to cisplatin correlated with the activities of DNA-PK/Ku86, but not with the Ku70 or other clinical parameters such as age, sex of the patients, pathological gradings of the tumors, or tumor size. The levels of DNA-PK activities also associated with pathological grading and Ku86, but not with other clinical parameters. The tumors of the patients who failed to respond to cisplatin-based chemotherapy tended to display higher activity levels of DNA-PK and Ku86. Furthermore, platinum-based chemotherapy did not result in significant changes of DNA-PK/Ku activities in four matched samples before and after chemotherapy. CONCLUSION: Pretreatment determination of DNA-PK/Ku86 activities might be helpful in identifying patients who will actually benefit from platinum-based treatment.
Authors: Mário H G Faria; Bronner P A Gonçalves; Régia M do S V do Patrocínio; Manoel O de Moraes-Filho; Silvia H B Rabenhorst Journal: Neuropathology Date: 2006-12 Impact factor: 1.906
Authors: Martina Bauer; Michael Goldstein; Markus Christmann; Huong Becker; Daniel Heylmann; Bernd Kaina Journal: Proc Natl Acad Sci U S A Date: 2011-12-12 Impact factor: 11.205
Authors: Patricia Rosa de Araujo; Aparna Gorthi; Acarizia E da Silva; Sonal S Tonapi; Dat T Vo; Suzanne C Burns; Mei Qiao; Philip J Uren; Zhi-Min Yuan; Alexander J R Bishop; Luiz O F Penalva Journal: Am J Pathol Date: 2016-07-25 Impact factor: 4.307
Authors: Ya-Ting Yang; Curt Balch; Samuel K Kulp; Michael R Mand; Kenneth P Nephew; Ching-Shih Chen Journal: Neoplasia Date: 2009-06 Impact factor: 5.715